AlloLife Biotechnology

AlloLife Biotechnology is a China-based biopharmaceutical company specializing in the development of next-generation, off-the-shelf cell therapies. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create standardized, scalable, and cost-effective immune cell products, including iPSC-derived Natural Killer (iNK) cells and T cells. AlloLife's primary focus is on addressing unmet medical needs in oncology and autoimmune diseases through the engineering of universal cell products that do not require patient-specific customization. By utilizing advanced gene editing and differentiation technologies, the company aims to overcome the limitations of traditional autologous CAR-T therapies, such as high costs and manufacturing complexity.